Familial hypercholesterolaemia: identification and management
KEYWORDS: people, healthcare, disease, therapy, coronary, healthcare professionals, professionals, children, heart disease, coronary heart, heart, concentration, risk, ldl-c, drug

coronary heart disease in early adulthood, healthcare professionals with expertise in FH in children and young people should consider offering: • a higher dose of statin than is licensed for use in the appropriate age group and/or • more than 1 lipid-modifying drug therapy and/or • lipid-modifying drug therapy before the age of 10 years. [2008] 1.3.1.25 In children and young people with homozygous FH, LDL-C concentration may be lowered by lipid-modifying drug therapy and this should be considered before LDL apheresis (see the section on specialist treatment). [2008] 1.3.1.26 In children and young people with FH who are intolerant of statins, healthcare professionals should consider offering other lipid-modifying drug therapies capable of reducing LDL-C concentration (such as bile acid sequestrants [resins], fibrates or ezetimibe). [2008] 1.3.1.27 Routine monitoring of growth and pubertal development in children and young people with FH is recommended. [2008] Adults and children and young people 1.3.1.28 Decisions about the choice of treatment should be made following discussion with the adult or child and young person and their parent or carer, and be informed by consideration of concomitant medication, comorbidities, safety and tolerability. [2008] 1.3.1.29 Healthcare professionals should consider offering fat-soluble vitamin (vitamins A, D and
